BRCA1 and neoplasm: Further supporting this observation, mouse models of BRCA1 mutant breast and ovarian cancer show that PARPi treatment, in addition to mediating cytotoxicity via synthetic lethality, triggers T cell-dependent anti-tumor immunity [117,118].